Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization

被引:20
|
作者
Lewis, Anna C. F. [1 ,2 ]
Perez, Emma F. [2 ,3 ]
Prince, Anya E. R. [4 ]
Flaxman, Hana R. [5 ]
Gomez, Lizbeth [3 ]
Brockman, Deanna G. [6 ]
Chandler, Paulette D. [2 ]
Kerman, Benjamin J. [2 ]
Lebo, Matthew S. [3 ,7 ,8 ,9 ]
Smoller, Jordan W. [10 ,11 ,12 ]
Weiss, Scott T. [2 ,13 ]
Zawatksy, Carrie L. Blout [2 ,9 ,14 ,15 ]
Meigs, James B. [8 ,9 ,16 ]
Green, Robert C. [2 ,8 ,9 ,14 ,17 ]
Vassy, Jason L. [8 ,14 ,18 ,19 ]
Karlson, Elizabeth W. [2 ,3 ,8 ]
机构
[1] Harvard Univ, EJ Safra Ctr Eth, Cambridge, MA 02138 USA
[2] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA
[3] Mass Gen Brigham Personalized Med, Boston, MA USA
[4] Univ Iowa, Coll Law, Iowa City, IA 52242 USA
[5] Weill Cornell Med Coll, New York, NY USA
[6] Color Hlth, Burlingame, CA USA
[7] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA
[8] Harvard Med Sch, Boston, MA 02115 USA
[9] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA USA
[10] Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA USA
[11] Massachusetts Gen Hosp, Ctr Precis Psychiat, Boston, MA USA
[12] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA
[13] Channing Div Network Med, Boston, MA USA
[14] Ariadne Labs, Populat Precis Hlth, Boston, MA USA
[15] MGH Inst Hlth Profess, Boston, MA USA
[16] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA USA
[17] Mass Gen Brigham Personalized Med, Cambridge, MA USA
[18] Vet Affairs Boston Healthcare Syst, Boston, MA USA
[19] Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, Boston, MA USA
关键词
Polygenic risk scores; Report design; Preventative medicine; Personalized medicine; Qualitative semi-structured interviews; JOINT CONSENSUS RECOMMENDATION; MEDICAL GENETICS; AMERICAN-COLLEGE; COMMUNICATION; STANDARDS; VARIANTS; GENOMICS; DISEASE;
D O I
10.1186/s13073-022-01117-8
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Polygenic risk scores (PRS), which offer information about genomic risk for common diseases, have been proposed for clinical implementation. The ways in which PRS information may influence a patient's health trajectory depend on how both the patient and their primary care provider (PCP) interpret and act on PRS information. We aimed to probe patient and PCP responses to PRS clinical reporting choices Methods Qualitative semi-structured interviews of both patients (N=25) and PCPs (N=21) exploring responses to mock PRS clinical reports of two different designs: binary and continuous representations of PRS. Results Many patients did not understand the numbers representing risk, with high numeracy patients being the exception. However, all the patients still understood a key takeaway that they should ask their PCP about actions to lower their disease risk. PCPs described a diverse range of heuristics they would use to interpret and act on PRS information. Three separate use cases for PRS emerged: to aid in gray-area clinical decision-making, to encourage patients to do what PCPs think patients should be doing anyway (such as exercising regularly), and to identify previously unrecognized high-risk patients. PCPs indicated that receiving "below average risk" information could be both beneficial and potentially harmful, depending on the use case. For "increased risk" patients, PCPs were favorable towards integrating PRS information into their practice, though some would only act in the presence of evidence-based guidelines. PCPs describe the report as more than a way to convey information, viewing it as something to structure the whole interaction with the patient. Both patients and PCPs preferred the continuous over the binary representation of PRS (23/25 and 17/21, respectively). We offer recommendations for the developers of PRS to consider for PRS clinical report design in the light of these patient and PCP viewpoints. Conclusions PCPs saw PRS information as a natural extension of their current practice. The most pressing gap for PRS implementation is evidence for clinical utility. Careful clinical report design can help ensure that benefits are realized and harms are minimized.
引用
下载
收藏
页数:16
相关论文
共 50 条
  • [1] Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization
    Anna C. F. Lewis
    Emma F. Perez
    Anya E. R. Prince
    Hana R. Flaxman
    Lizbeth Gomez
    Deanna G. Brockman
    Paulette D. Chandler
    Benjamin J. Kerman
    Matthew S. Lebo
    Jordan W. Smoller
    Scott T. Weiss
    Carrie L. Blout Zawatksy
    James B. Meigs
    Robert C. Green
    Jason L. Vassy
    Elizabeth W. Karlson
    Genome Medicine, 14
  • [2] Development of a clinical assay for reporting polygenic risk scores
    Lebo, Matthew
    Hao, Limin
    Berriz, Gabriel
    Danowski, Morgan
    Koch, Christopher
    Kumar, Prathik Korategere
    Lewis, Anna
    Parpattedar, Shruti
    Steeves, Marcie
    Yu, Wanfeng
    Kraft, Peter
    Vassy, Jason
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 : S217 - S217
  • [3] Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk Clinical Perspectives and Basic Implications
    Aragam, Krishna G.
    Natarajan, Pradeep
    CIRCULATION RESEARCH, 2020, 126 (09) : 1159 - 1177
  • [4] Potential use of clinical polygenic risk scores in psychiatry - ethical implications and communicating high polygenic risk
    Palk, A. C.
    Dalvie, S.
    de Vries, J.
    Martin, A. R.
    Stein, D. J.
    PHILOSOPHY ETHICS AND HUMANITIES IN MEDICINE, 2019, 14 (1)
  • [5] Potential use of clinical polygenic risk scores in psychiatry – ethical implications and communicating high polygenic risk
    A. C. Palk
    S. Dalvie
    J. de Vries
    A. R. Martin
    D. J. Stein
    Philosophy, Ethics, and Humanities in Medicine, 14
  • [6] Clinical Implications of Integrating Polygenic Risk Into Established Cardiovascular Disease Risk Scores
    Riveros-Mckay, Fernando
    Selzam, Saskia
    Seth, Priyanka
    Moore, Rachel
    Tarran, William A.
    O'Sullivan, Jack W.
    Ashley, Euan A.
    McVean, Gilean
    Plagnol, Vincent
    Donnelly, Peter
    Weale, Michael E.
    CIRCULATION, 2021, 144
  • [7] On the utilization of polygenic risk scores for therapeutic targeting
    Gibson, Greg
    PLOS GENETICS, 2019, 15 (04):
  • [8] Binary vs. continuous: understanding provider and patient preference for polygenic risk score reporting
    Lewis, Anna
    Perez, Emma
    Prince, Anya
    Vassy, Jason
    Flaxman, Hana
    Gomez, Lizbeth
    Zawatsky, Carrie Blout
    Brockman, Deanna
    Meigs, James
    Kerman, Benjamin
    Lebo, Matthew
    Chandler, Paulette
    Weiss, Scott
    Smoller, Jordan
    Green, Robert
    Karlson, Elizabeth
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 : S292 - S293
  • [9] Implementation and implications for polygenic risk scores in healthcare
    John L. Slunecka
    Matthijs D. van der Zee
    Jeffrey J. Beck
    Brandon N. Johnson
    Casey T. Finnicum
    René Pool
    Jouke-Jan Hottenga
    Eco J. C. de Geus
    Erik A. Ehli
    Human Genomics, 15
  • [10] Implementation and implications for polygenic risk scores in healthcare
    Slunecka, John L.
    van der Zee, Matthijs D.
    Beck, Jeffrey J.
    Johnson, Brandon N.
    Finnicum, Casey T.
    Pool, Rene
    Hottenga, Jouke-Jan
    de Geus, Eco J. C.
    Ehli, Erik A.
    HUMAN GENOMICS, 2021, 15 (01)